NPI 1154406411: Open Payments
NPI 1154406411. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$747 in 38 payments from 9 companies in 2025. Trend: 2023 $460 · 2024 $1,705 · 2025 $747
Food & beverage: $737Education: $9
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 8 | $146 |
| Alkermes, Inc. | 9 | $144 |
| Neurocrine BioSciences, Inc. | 6 | $129 |
| AbbVie Inc. | 4 | $79 |
| Lundbeck LLC | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Bausch Health US, LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
Products named: REXULTI, INGREZZA, Auvelity, VRAYLAR, VIVITROL, ARISTADA, FANAPT, APLENZIN.
